Drugs for Vulva Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 100)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Octreotide |
Approved, Investigational |
Phase 3 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
2 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
3 |
|
Vaccines |
|
Phase 3 |
|
|
|
4 |
|
Hemostatics |
|
Phase 3 |
|
|
|
5 |
|
Antineoplastic Agents, Hormonal |
|
Phase 3 |
|
|
|
6 |
|
Gastrointestinal Agents |
|
Phase 3 |
|
|
|
7 |
|
Fibrin Tissue Adhesive |
|
Phase 3 |
|
|
|
8 |
|
Coagulants |
|
Phase 3 |
|
|
|
9 |
|
Bupropion |
Approved |
Phase 2 |
|
31677-93-7, 34841-39-9, 34911-55-2 |
444 |
Synonyms:
(+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
Amfebutamona
Amfebutamone
AMFEBUTAMONE HCL
amfebutamone|BW-323|Wellbutrin®|Zyban®
Amfebutamonum
BUPROPION
BUPROPION HCL
Bupropion hydrochloride
Bupropion hydrochloride, (+-)-isomer
Bupropion, (+-)-isomer
BW-323
Esteve brand OF bupropion hydrochloride
FORFIVO XL
glaxo Wellcome brand 1 OF bupropion hydrochloride
|
glaxo Wellcome brand 2 OF bupropion hydrochloride
glaxo Wellcome brand 3 OF bupropion hydrochloride
GlaxoSmithKline brand 1 OF bupropion hydrochloride
GlaxoSmithKline brand 2 OF bupropion hydrochloride
NSC-315851
Quomen
Wellbatrin
Wellbutrin
WELLBUTRIN 100
WELLBUTRIN 75
WELLBUTRIN SR
WELLBUTRIN XL
Zyban
Zyban (anti-smoking)
Zyban (bupropion)
Zyntabac
|
|
10 |
|
Dopamine |
Approved |
Phase 2 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
11 |
|
Fondaparinux |
Approved, Investigational |
Phase 2 |
|
114870-03-0, 104993-28-4 |
5282448 636380 |
Synonyms:
Arixtra
Arixtra®
Fondaparinux
Fondaparinux sodium
FONDAPARINUX SODIUM FOR ASSAY
FONDAPARINUX SODIUM IDENTIFICATION
|
IC-851589
Natural heparin pentasaccharide
ORG-31540
Quixidar
SR-90107A
|
|
12 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
13 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
14 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
15 |
|
Bleomycin |
Approved, Investigational |
Phase 2 |
|
9041-93-4, 11056-06-7 |
5360373 |
Synonyms:
Almirall brand OF bleomycin sulfate
Bellon brand OF bleomycin sulfate
Bellon, bléomycine
Blanoxan
Blenoxane
Bleo
Bleo cell
Bleo-cell
BLEOcell
Bleocin
BLEO-KYOWA
Bleolem
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin
Bleomycin a(2)
Bleomycin a2
Bleomycin b(2)
Bleomycin b2
BLEOMYCIN HYDROCHLORIDE
|
Bleomycin sulfate
Bleomycin sulphate
Bleomycine
Bleomycine [INN-French]
Bléomycine bellon
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
Bleomycinum mack
BLM
Bristol myers squibb brand OF bleomycin sulfate
Bristol-myers squibb brand OF bleomycin sulfate
Bull brand OF bleomycin sulfate
Cell pharm brand OF bleomycin sulfate
Lemery brand OF bleomycin sulfate
Lundbeck brand OF bleomycin sulfate
Mack brand OF bleomycin sulfate
Mack, bleomycinum
NSC-125066
Sulfate, bleomycin
|
|
16 |
|
Atezolizumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
17 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 1, Phase 2 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
18 |
|
Niraparib |
Approved, Investigational |
Phase 1, Phase 2 |
|
1038915-60-4 |
24958200 |
Synonyms:
COMPOUND 56 [PMID 19873981]
compound 56 [PMID 19873981]|MK 4827|MK-4827|Zejula®
JNJ-64091742
MK 4827
|
MK4827
MK-4827
NIRAPARIB
ZL-2306
|
|
19 |
|
Irinotecan |
Approved, Investigational |
Phase 1, Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
20 |
|
Fluorouracil |
Approved |
Phase 1, Phase 2 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
21 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
22 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
23 |
|
Vorinostat |
Approved, Investigational |
Phase 2 |
|
149647-78-9 |
5311 |
Synonyms:
18F Suberoylanilide hydroxamic acid
18F-SAHA
18F-Suberoylanilide hydroxamic acid
Merck brand OF vorinostat
MK0683
MK-0683
MK-0683|MK0683|SAHA|suberoylanilide hydroxamic acid|Zolinza®
N Hydroxy n' phenyloctanediamide
N1 Hydroxy N8 phenyloctanediamide
N1-Hydroxy-N8-phenyloctanediamide
NHNPODA
N-Hydroxy-n'-phenyloctanediamide
N-Hyrdroxy-n'-phenyloctanediamide
|
Octanedioate hydroxyamide phenylamide
Octanedioic acid hydroxyamide phenylamide
SAHA
SHH
Suberanilohydroxamate
Suberanilohydroxamic acid
Suberoyl anilide hydroxamic acid
Suberoylanilide hydroxamate
Suberoylanilide hydroxamic acid
VORINOSTAT
Vorinostatum
Zolinza
|
|
24 |
|
Fludarabine |
Approved |
Phase 1, Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
25 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 1, Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
26 |
|
Aldesleukin |
Approved |
Phase 1, Phase 2 |
|
110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukin
Aldesleukina
IL-2
ILT101
ILT-101
Interleukin-2 aldesleukin
|
INTERLEUKIN-2 PRECURSOR
Interleukin-2(2-133),125-ser
Recombinant human interleukin-2
Recombinant interleukin-2 human
T-CELL GROWTH FACTOR
TCGF
|
|
27 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
28 |
|
Entinostat |
Investigational |
Phase 1, Phase 2 |
|
209783-80-2 |
4261 |
Synonyms:
BAY 86-5274
BAY 86-5274|MS-275|SNDX-275|ZK 244894
BAY86-5274
ENTINOSTAT
Entinostatum
MS 27-275
MS 275
MS-27-275
|
MS-275
MS-275-27
N-(2-Aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide
N-[[4-[(2-Aminoanilino)-oxomethyl]phenyl]methyl]carbamate 3-pyridinylmethyl ester
N-[[4-[(2-Aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester
SNDX 275
SNDX-275
SNDX-275MS-275SID29217590
|
|
29 |
|
Dopamine Uptake Inhibitors |
|
Phase 2 |
|
|
|
30 |
|
Dopamine Agents |
|
Phase 2 |
|
|
|
31 |
|
Psychotropic Drugs |
|
Phase 2 |
|
|
|
32 |
|
Antidepressive Agents |
|
Phase 2 |
|
|
|
33 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2 |
|
|
|
34 |
|
HIV Protease Inhibitors |
|
Phase 2 |
|
|
|
35 |
|
protease inhibitors |
|
Phase 2 |
|
|
|
Synonyms:
|
36 |
|
Fibrinolytic Agents |
|
Phase 2 |
|
|
|
37 |
|
Factor Xa Inhibitors |
|
Phase 2 |
|
|
|
38 |
|
PENTA |
|
Phase 2 |
|
|
|
39 |
|
Anticoagulants |
|
Phase 2 |
|
|
|
40 |
|
Serine Proteinase Inhibitors |
|
Phase 2 |
|
|
|
41 |
|
Antithrombins |
|
Phase 2 |
|
|
|
42 |
|
Antithrombin III |
|
Phase 2 |
|
|
|
43 |
|
Immunologic Factors |
|
Phase 1, Phase 2 |
|
|
|
44 |
|
Albumin-Bound Paclitaxel |
|
Phase 2 |
|
|
|
45 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
46 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
47 |
|
Alkylating Agents |
|
Phase 1, Phase 2 |
|
|
|
48 |
|
Antirheumatic Agents |
|
Phase 1, Phase 2 |
|
|
|
49 |
|
Antineoplastic Agents, Alkylating |
|
Phase 1, Phase 2 |
|
|
|
50 |
|
Anti-Infective Agents |
|
Phase 1, Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 146)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women |
Completed |
NCT00092521 |
Phase 3 |
|
2 |
A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women |
Completed |
NCT00543543 |
Phase 3 |
|
3 |
Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy |
Completed |
NCT00033605 |
Phase 3 |
octreotide acetate |
4 |
A Phase III Clinical Trial Use of TISSEEL VH Fibrin Sealant to Reduce Lymphedema Incidence After Inguinal Lymph Node Dissection Performed in the Management of Vulvar Malignancies |
Completed |
NCT00028951 |
Phase 3 |
fibrin sealant |
5 |
Phase III Radiation Therapy vs Pelvic Node Resection for Previously Untreated Invasive Squamous Cell Carcinoma of the Vulva With Positive Groin Nodes |
Completed |
NCT00898352 |
Phase 3 |
|
6 |
A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds) |
Completed |
NCT00943722 |
Phase 3 |
|
7 |
An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) |
Completed |
NCT03158220 |
Phase 3 |
|
8 |
A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years |
Completed |
NCT04425291 |
Phase 3 |
|
9 |
Intraoperative Lymphatic Mapping in Patients With Stage I and II Squamous Carcinoma of the Vulva |
Completed |
NCT00003325 |
Phase 3 |
|
10 |
A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged16-26 Years |
Completed |
NCT05372016 |
Phase 3 |
|
11 |
A Phase III Open-label Safety and Immunogenicity Study of GARDASILâ„¢9 Administered to 9- to 26-Year-Old Females and Males in Vietnam |
Completed |
NCT03546842 |
Phase 3 |
|
12 |
Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage. |
Completed |
NCT00224744 |
Phase 3 |
|
13 |
A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASILâ„¢ |
Completed |
NCT01047345 |
Phase 3 |
|
14 |
Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial |
Recruiting |
NCT04895020 |
Phase 3 |
|
15 |
A Multicenter,Randomized,Blind and Positive-Controlled Phase â…¢ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years |
Recruiting |
NCT04422366 |
Phase 3 |
|
16 |
Reliability of Indocyanine Green Use in Sentinel Lymph Node Identification in Cancer Surgery |
Recruiting |
NCT02997553 |
Phase 3 |
Indocyanine green;Technetium99 |
17 |
A Prospective Randomized Single Blind Phase III Trial Comparing Flexitouch Home Maintenance Therapy to Standard Home Maintenance Therapy for Lower Extremity Lymphedema Resulting From Treatment of Gynecologic Malignancy |
Terminated |
NCT00577317 |
Phase 3 |
|
18 |
A Randomized Study of Adjuvant Radiation Treatment Versus Radiation and Chemotherapy in Patients With Vulvar Cancer and Involved Nodes |
Terminated |
NCT00006096 |
Phase 3 |
cisplatin |
19 |
Systematic Nutritional Care in Patients Receiving First-line Chemotherapy for Metastatic Gynecologic Cancer in a Phase II Study |
Unknown status |
NCT00905658 |
Phase 2 |
|
20 |
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer |
Completed |
NCT03180294 |
Phase 2 |
Bupropion 150 mg XL;Placebo |
21 |
A Limited Access Phase II Trial Utilizing Bioimpedance to Measure Lower Extremity Lymphedema Associated With the Surgical Management of a Vulvar Cancer |
Completed |
NCT01406769 |
Phase 2 |
|
22 |
A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies |
Completed |
NCT01079832 |
Phase 2 |
|
23 |
Psychosexual Intervention for Gynecologic and Breast Cancer Patients |
Completed |
NCT01764802 |
Phase 2 |
|
24 |
A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva |
Completed |
NCT00068406 |
Phase 2 |
Cisplatin |
25 |
A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women |
Completed |
NCT00551187 |
Phase 2 |
|
26 |
A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women |
Completed |
NCT00520598 |
Phase 2 |
Comparator: V505 formulation 2 |
27 |
The Impact of the Self-management Intervention "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence: A Mixed-Methods Project |
Completed |
NCT01986725 |
Phase 2 |
|
28 |
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial |
Completed |
NCT00381888 |
Phase 2 |
fondaparinux sodium |
29 |
Effectiveness of an Individualized Symptom Education Program (ISEP) on the Symptom Distress of Women Receiving Radiation for Gynecological Cancer. |
Completed |
NCT00275353 |
Phase 2 |
|
30 |
Phase II Clinical Trial On Taxol As Single Agent In Locally Advanced And/Or Metastatic Or Recurrent Vulva Cancer Not Amenable For Surgery And/Or Radiotherapy |
Completed |
NCT00014599 |
Phase 2 |
paclitaxel |
31 |
A Pilot Study Evaluating The Safety Of Avastin And Pelvic Radiation In Women With Pelvic-Confined Recurrence of Gynecological Cancers |
Completed |
NCT00545792 |
Phase 2 |
Avastin |
32 |
A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO) |
Completed |
NCT01399658 |
Phase 2 |
3'-Deoxy-3'-18f-Fluorothymidine |
33 |
Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize) |
Recruiting |
NCT04192253 |
Phase 2 |
Paclitaxel and Carboplatin |
34 |
Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy (CRAVAT) |
Recruiting |
NCT04161664 |
Phase 2 |
Paclitaxel and Carboplatin |
35 |
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) |
Recruiting |
NCT02628067 |
Phase 2 |
|
36 |
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors |
Recruiting |
NCT02834013 |
Phase 2 |
|
37 |
A Randomized Phase II Trial of Adjuvant Nivolumab With or Without Cabozantinib in Patients With Resected Mucosal Melanoma |
Recruiting |
NCT05111574 |
Phase 2 |
Cabozantinib S-malate;Placebo Administration |
38 |
Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer: the ElechtraPlatinum Study. A Randomized Controlled Trial |
Recruiting |
NCT05395962 |
Phase 2 |
Carboplatin;Bleomycin |
39 |
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III, a Prospective Phase II Treatment Trial |
Recruiting |
NCT05076942 |
Phase 2 |
Cisplatin |
40 |
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers |
Recruiting |
NCT04708470 |
Phase 1, Phase 2 |
Bintrafusp Alfa;NHS-IL12;Entinostat |
41 |
A Multilevel Intervention (Potlako+) to Improve Timely Cancer Detection and Treatment |
Recruiting |
NCT04141449 |
Phase 2 |
|
42 |
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers ( Adaptive PET II) |
Recruiting |
NCT03403465 |
Phase 2 |
|
43 |
A Phase 2 Study of Combined Chemo-immunotherapy With Cisplatin-pembrolizumab and Radiation for Unresectable Vulvar Squamous Cell Carcinoma |
Recruiting |
NCT04430699 |
Phase 2 |
Cisplatin;Pembrolizumab |
44 |
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types |
Recruiting |
NCT05000294 |
Phase 1, Phase 2 |
Atezolizumab;Tivozanib |
45 |
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers |
Recruiting |
NCT02858310 |
Phase 1, Phase 2 |
Aldesleukin;Fludarabine;Cyclophosphamide |
46 |
A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies |
Recruiting |
NCT03221400 |
Phase 1, Phase 2 |
PEN-866 Sodium;fluorouracil;Folinic acid;Niraparib |
47 |
A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers |
Active, not recruiting |
NCT03439085 |
Phase 2 |
|
48 |
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061) |
Active, not recruiting |
NCT01595061 |
Phase 2 |
Cisplatin;Gemcitabine Hydrochloride |
49 |
Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma |
Active, not recruiting |
NCT04357873 |
Phase 2 |
pembrolizumab; vorinostat |
50 |
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated Cancers |
Not yet recruiting |
NCT05639972 |
Phase 1, Phase 2 |
Conditioning, E7 TCR-T cells, and aldesleukin |
Cochrane evidence based reviews: vulvar neoplasms
|